A Systematic Review and Meta-Analysis of Immunogenicity and Safety of the Influenza Vaccine in COPD Patients, and Its Relevance with Real-World Effectiveness
International Journal of Chronic Obstructive Pulmonary Disease · 2026
DOI: 10.2147/copd.s561711 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2026. Verfasst von Resti Yudhawati und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia. Hauptthemen laut MEDLINE: Influenza Vaccines, Pulmonary Disease, Chronic Obstructive, Influenza, Human, Immunogenicity, Vaccine. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: COPD
Abstract (Originalsprache)
Objective
A systematic review and meta-analysis was conducted to evaluate the immunogenicity and adverse events of influenza vaccines in patients with chronic obstructive pulmonary disease (COPD) and explored their relevance to real-world vaccine effectiveness (VE).
Methods
A systematic search of PubMed, Cochrane Library (Wiley), Google Scholar, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform using keywords of "influenza vaccine", "immunogenicity", "COPD", and "Chronic Obstructive Pulmonary Disease" to identify relevant studies published up to April 24, 2024. These are randomized controlled trials and cross-sectional, prospective, and observational studies that included COPD patients, particularly those aged ≥50 years, which assessed the immunogenicity of inactivated trivalent and quadrivalent, split-virion influenza vaccines. The outcomes were geometric mean titer (GMT), seroprotection rate (SPR), seroconversion rate (SCR), and safety.
Results
Six studies involving 672 participants were retrieved. The pooled SCR in the intradermal subgroup was highest for A/H1N1 (68.6% [95% CI = 48.6-83.5%]) and A/H3N2 (65.8% [95% CI = 57.9-73.0%]). SPR was highest via subcutaneous route, reaching 96.0% for A/H3N2 however only one study was available, hence the findings should be interpreted with caution. The pooled mean difference in GMT was higher for intradermal than intramuscular vaccination, particularly for the A/H1N1 strain (8.38 vs 7.98) and A/H3N2 (7.97 vs 7.44). Local adverse events were more frequent with intradermal vaccination, particularly erythema (31.5%) and swelling (28.7%), while systemic events such as fever were rare (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.
- Department of Pulmonology and Respiratory Medicine, Dr. Soetomo General Academic Hospital, Surabaya, East Java, Indonesia.
- Department of Pulmonology and Respiratory Medicine, Universitas Airlangga Teaching Hospital, Surabaya, East Java, Indonesia.
- Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.
ORCID-Profile: Resti Yudhawati
Zitieren
APA
Yudhawati, R., Aini, F. N., & Wicaksono, N. F. (2026). A Systematic Review and Meta-Analysis of Immunogenicity and Safety of the Influenza Vaccine in COPD Patients, and Its Relevance with Real-World Effectiveness. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s561711
Vancouver
Yudhawati R, Aini FN, Wicaksono NF. A Systematic Review and Meta-Analysis of Immunogenicity and Safety of the Influenza Vaccine in COPD Patients, and Its Relevance with Real-World Effectiveness. International Journal of Chronic Obstructive Pulmonary Disease. 2026. doi:10.2147/copd.s561711
BibTeX
@article{Yudhawati2026,
author = {Yudhawati, Resti and Aini, Faradila Nur and Wicaksono, Nisrina Fitriyanti},
title = {A Systematic Review and Meta-Analysis of Immunogenicity and Safety of the Influenza Vaccine in COPD Patients, and Its Relevance with Real-World Effectiveness},
journal = {International Journal of Chronic Obstructive Pulmonary Disease},
year = {2026},
doi = {10.2147/copd.s561711}
}
EUVIMED